Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objective is to demonstrate the superiority of TMC435 versus placebo as part of a treatment regimen including peginterferon alpha-2a (PegIFNα-2a)/ribavirin (RBV) or PegIFNα-2b/RBV, with respect to the proportion of treatment-naïve genotype 1 HCV-infected subjects with sustained virologic response (SVR) 12 weeks after the planned end of treatment (SVR12).
Critère d'inclusion
- Hepatitis C Virus (HCV) in treatment naïve patients